Australian clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has received approval from Human Research Ethics Committee (HREC) to initiate a Phase I clinical trial of PD1-Vaxx in Australia.
A comprehensive cancer hospital situated in Sydney, Chris O’Brien Lifehouse is the first one to attain ethics approval. Further clinical sites will be opened in Australia as well as the US, following an FDA (Food and Drug Administration) investigational new drug (IND).
Imugene notified that the ethics approval process represents the first independent review of PD1-Vaxx pre-clinical efficacy and safety data.
As at 12:51 PM AEST, IMU traded at $0.035, with a rise of ~3%.
Penny stocks have been known to attract investors who are looking for explosive gains and it is possible to get lucky with these typically speculative investments. Just as the name suggests, penny stocks trade at low prices and are common shares of small public companies.
Get an exclusive insight into the features of penny stocks along with their pros and cons. Read about what you should be wary about when figuring out ways to invest in them, so that the possibility for big rewards does not tend to outweigh the risks.